Academic Journal
Evaluating the toxicity of capecitabine-cisplatin versus gemcitabine-cisplatin regimens for palliative chemotherapy in advanced biliary tract carcinoma
| العنوان: | Evaluating the toxicity of capecitabine-cisplatin versus gemcitabine-cisplatin regimens for palliative chemotherapy in advanced biliary tract carcinoma |
|---|---|
| المؤلفون: | Hasan, Tariq, Rahid Sarwar, S. M., Sarkar, Fatema, Jahan, Ishrat, Mostari, M. Shabnam |
| المصدر: | International Journal of Research in Medical Sciences; Vol. 12 No. 3 (2024): March 2024; 716-721 ; 2320-6012 ; 2320-6071 |
| بيانات النشر: | Medip Academy |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Carcinoma, Biliary, Gemcitabine, Capecitabine, Cisplatin, Efficacy |
| الوصف: | Background: Advanced biliary tract carcinoma is a malignancy associated with poor prognosis and limited treatment options. This study aimed to compare the treatment effects in terms of toxicities of Capecitabine-Cisplatin and Gemcitabine-Cisplatin regimens as palliative chemotherapy for ABTC in Bangladesh. Methods: This quasi-experimental study was conducted at the Department of Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, involving 78 patients with histopathologically confirmed ABTC (AJCC Stage IV). Participants were divided into two groups: Arm-A received Capecitabine-Cisplatin, and Arm-B received Gemcitabine-Cisplatin. Treatment response, hematological and non-hematological toxicities were assessed and compared between the two groups. Results: No significant differences in baseline demographic and clinical characteristics were observed between the two groups. Arm-A demonstrated a higher rate of partial response in the final assessment (51.28% vs. 41.03%, p=0.029). Acute hematological toxicities were more frequent in Arm-B, with a higher incidence of Grade 2 and 3 anemia, neutropenia, and leukopenia (p<0.05). Non-hematological toxicities were comparable, except for Hand-Foot Syndrome, which was significantly higher in Arm-A (p=0.03). Conclusions: The Capecitabine-Cisplatin regimen exhibited a different toxicity profile compared to the Gemcitabine-Cisplatin regimen for palliative chemotherapy in advanced biliary tract carcinoma. While both regimens were generally well-tolerated, the Capecitabine-Cisplatin regimen demonstrated lower incidences of hematological toxicities. These findings emphasize the importance of considering toxicity profiles when selecting treatment options for patients with advanced biliary tract carcinoma. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | https://www.msjonline.org/index.php/ijrms/article/view/13009/8474; https://www.msjonline.org/index.php/ijrms/article/view/13009 |
| DOI: | 10.18203/2320-6012.ijrms20240512 |
| الاتاحة: | https://www.msjonline.org/index.php/ijrms/article/view/13009 https://doi.org/10.18203/2320-6012.ijrms20240512 |
| Rights: | Copyright (c) 2024 International Journal of Research in Medical Sciences |
| رقم الانضمام: | edsbas.64DE84E1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.18203/2320-6012.ijrms20240512 |
|---|